Reducing drug resistance in acute myeloid leukaemia patients
Researchers conducted a proteogenomic characterisation and found that drug exposure changes drug sensitivity.
List view / Grid view
Researchers conducted a proteogenomic characterisation and found that drug exposure changes drug sensitivity.
A new study proves that organoid drug testing is highly accurate at predicting effective treatments and finds a novel therapeutic option.
While blood tests measuring prostate-specific antigen (PSA) levels have been a primary screening tool, their limitations in specificity have led to challenges such as overdiagnosis and overtreatment. Cleveland Diagnostics is pioneering an alternative approach with the IsoPSA test, focusing on assessing the structure of the PSA protein rather than its…
Researchers suggest that DA histology slowly emerges by accumulating burdens of DNA damage and copy number aberrations.
Learn about the different types of multiplexed imaging available, as well as their applications, benefits and disadvantages.
This app note explores a groundbreaking multiplex immunodetection approach to identify cancer stem cell niches within hepatocellular carcinoma (HCC).
A novel technology can reduce tumour sizes significantly and improve treatment efficacy when used with existing immunotherapy.
For the first time, mitochondrial DNA mutations could be used with immunotherapy to increase the chances of successful treatments.
The Ku70 protein prevents cancer cells from becoming more aggressive and metastasising. It could also be used as an immune biomarker.
Download this report to discover more about human derived induced pluripotent stem cells (hiPSCs), the suitability of NK cells for cancer therapy and the latest research into Alzheimer’s disease.
Scientists demonstrate how disrupting the Cx26 molecular complex in triple-negative breast cancer cells slowed tumour growth.
Researchers observed significant upregulation of Siglec-15 in the tumour microenvironment in bone tumour samples from breast cancer patients.
Researchers discover that blocking PD-L2 in senescent cells increases the efficacy of chemotherapy in mouse models.
PLK4 inhibition could be a novel therapeutic for an acute myeloid leukaemia subtype carrying the TP53 mutation.
A patient-specific organ-on-a-chip model of cholangiocarcinoma, with its tumour microenvironment, helps to predict therapy response.